Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewThe commercial corporation of advanced therapies, an opportunity to leverage Spanish devel...
The Spanish biotech industry is present throughout the value chain of advanced therapy development and manufacturing, with 47 entities working in this field. Over 30 biotechnology companies have
-
Press releaseThe commercial corporation of advanced therapies, an opportunity to leverage Spanish devel...
With the creation of this commercial corporation, it is expected to "bring two advanced therapies to authorization and commercialization in 2027 manufactured in Spain." The Spanish biotech industry is
-
NewBiotechnology to reduce the risk of kidney transplant failure and adverse events related t...
On the occasion of World Kidney Day, we interviewed Isabel Portero, founder and CEO of Biophope, a biotechnology company focused on precision medicine in the areas of immunosuppression and autoimmune
-
NewAseBio, AESEMI, Cotec Foundation, and Secpho celebrate the launch by the Ministry of Scien...
The future Deep Tech Strategy takes up the challenge of the proposal for the creation of a High Commissioner for Deep Strategic Technologies made jointly by the four entities.
-
Press release
AseBio, AESEMI, Cotec Foundation, and Secpho celebrate the launch by the Ministry of Scien...
The future Deep Tech Strategy takes up the challenge of the proposal for the creation of a High Commissioner for Deep Strategic Technologies made jointly by the four entities. We consider that the
-
NewMahana Therapeutics acquires Cara Care (Asabys) to become a global platform for digital th...
The combination creates a global company that offers the most comprehensive digestive health portfolio available today.
-
EventGlobal DAO Congress
DR Healthcare launches the III edition of the Global DAO Congress (#DAO24), an event on the field of Diamine Oxidase enzyme research and management, which will be held on April 11, 2024 and can be
-
NewAbilityPharma closes €7 million round for metastatic pancreatic cancer drug ABTL0812
AbilityPharma closes €7 million round to fully fund its international Phase 2b clinical trial with the antitumor drug ABTL0812 in pancreatic cancer patients.
-
NewAseBio Investor Day 2024 focuses on the increasing interest of investors in the bioeconomy...
The benchmark event for investors and biotechnology companies will host a panel discussion focused on the challenge of investing in start-ups and companies active in the bioeconomy sector in Spain.
-
New#GaleríaAseBio | This was the meeting "Women biotech for a better science and innovation".
On the occasion of International Women's Day, AseBio organized the first session "Biotech women for a better science and innovation", a meeting that brought together students and professionals from
-
New
The biotechnology sector, spearheading women's leadership in Spain
We organize the event "Women in Biotech for Better Science and Innovation," highlighting the significant role of women in the biotechnology industry.
-
Press release
The biotechnology sector, spearheading women's leadership in Spain
AseBio organizes the event "Women in Biotech for Better Science and Innovation," highlighting the significant role of women in the biotechnology industry. In addition, the names of professional women
-
NewPatient-Centric Design in the Development of Healthcare Solutions
How can Life Sciences companies ensure that the solutions they spend years developing truly respond to patient needs?
-
NewWhere to find Biobide in March 2024 🔎
Meet our team at the 2024 Society of Toxicology (SOT) Annual Meeting and ToxExpo We will also attend BioEurope Spring 2024, the partnering event for biotech and pharma companies!
-
NewWhere to find BIAT GROUP in March 2024 🔎
2024 Smart Agrifood Summit; TRANSFIERE 2024, 3rd European Meeting on Science, Technology and Innovation!
-
NewSpanish researchers to design proteins using AI to make advanced therapies more efficient
The project will be undertaken by a public-private consortium formed by VIVEbiotech, Integra Therapeutics and OneChain Immunotherapeutics, the UPF, the IBMB-CSIC and the CIEMAT over the next four
-
CompanyLILLY, S.A.U.
-
NewOneChain Immunotherapeutics has received 1.3M euro grant to advance a new promising CAR T ...
A consortium led by the Spanish company OneChain Immunotherapeutics has received 1.9M euros from the Spanish Ministry of Science and Innovation to advance a groundbreaking therapy, based on CAR T
-
NewBiotechnology, crucial in addressing the global challenge posed by rare diseases
Biotechnology is providing answers to rare diseases in areas with unresolved clinical needs such as diagnosis and treatment, through advanced therapies, biomarkers, and the development of new
-
Press release
Biotechnology emerges as a key player in the fight against rare diseases
In Spain, around three million people live with rare diseases or are in search of a diagnosis. Only 20% of the over 6,300 rare diseases identified in Europe are currently under investigation. In
-
NewStefanos Theoharis, new CEO of OneChain Immunotherapeutics
OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncologic diseases, announced Stefanos Theoharis as the